- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL introduces Apogee 800 Plus
Visitors to ATL's booth at next week's American Institute of Ultrasoundin Medicine meeting will get a glimpse of Apogee 800 Plus, theBothell, WA, company's newest platform. The scanner brings toa lower price point features found on ATL's premium HDI 3000
Visitors to ATL's booth at next week's American Institute of Ultrasoundin Medicine meeting will get a glimpse of Apogee 800 Plus, theBothell, WA, company's newest platform. The scanner brings toa lower price point features found on ATL's premium HDI 3000 scanner,according to Steve Anderson, director of value products.
Apogee 800 Plus builds on the Apogee 800 platform acquiredthrough ATL's purchase of Interspec. The new version featuresimage analysis packages first seen on HDI 3000, and has a new8-bit color processor and improved signal-to-noise ratio, thanksto improvements to Apogee 800's system receiver. The scanner willreplace ATL's Ultramark 4 in the mid-range segment (SCAN 2/14/96).Apogee 800 scanners in the field will be able to upgrade to thenew technology, Anderson said.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
